Skip to Main Content

Bluebird Bio (BLUE) won’t be selling the world’s most expensive drug. The second priciest? Yup.

Zynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced Friday. Only Zolgensma, the Novartis gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • My sister has beta thalassemia — I’m so happy that this treatment is real and is being brought to market.

Comments are closed.